Cytek Biosciences, Inc. reported $207M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $207M (to Q2 2026). Free cash flow: −$12M, trailing twelve months to Q2 2026. Operating margin: −23%, trailing twelve months to Q2 2026. EPS: −$0.62, trailing twelve months to Q2 2026.

CTKBCytek Biosciences, Inc.

Healthcare

$5.37+42% 1Y

$5.37

$3.3652 weeks$6.09

CTKB as reported

Cytek Biosciences, Inc. reported $207M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$207M

Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied

Free cash flow: −$12M
Free cash flow · −211% year on year · trailing twelve months to Q2 2026
Operating margin: −23%
Operating margin · trailing twelve months to Q2 2026
EPS: −$0.62
EPS · +1140% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CTKB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$207M	n/a	Q2 2026
Net income	−$14M	n/a	Q3 2023 · 11 quarters behind
EPS	−$0.62	+1140%	Q2 2026
Gross margin	53%	n/a	Q2 2026
Operating margin	−23%	n/a	Q2 2026
ROE	−1.2%	n/a	Q3 2023 · 11 quarters behind
ROA	−0.93%	n/a	Q3 2023 · 11 quarters behind
ROIC	−43%	n/a	Q2 2026
Free cash flow	−$12M	−211%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.